The Technical Analyst
Bellerophon Therapeutics [BLPH]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Bellerophon Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
14.68% $0.0586
America/New_York / 23 apr 2024 @ 14:13
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.717 mill |
| EPS: | -0.890 |
| P/E: | -0.0700 |
| Earnings Date: | Nov 14, 2023 |
| SharesOutstanding: | 12.23 mill |
| Avg Daily Volume: | 0.0458 mill |
| RATING 2024-04-22 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0700 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0700 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0536 - 0.0636 ( +/- 8.53%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-10-13 | Puissance Capital Management Lp | Sell | 1 076 841 | Common Stock |
| 2023-06-07 | Amin Naseem | Buy | 47 578 | Common Stock |
| 2023-06-07 | Fernandes Peter | Sell | 100 000 | Stock Options (Right to Buy) |
| 2023-06-07 | Shah Parag Suresh | Sell | 50 000 | Stock Options (Right to Buy) |
| 2023-06-07 | Dekker Martin | Sell | 50 000 | Stock Options (Right to Buy) |
| INSIDER POWER |
|---|
| -73.99 |
| Last 99 transactions |
| Buy: 6 532 145 | Sell: 5 633 542 |
Forecast:
15:53 - $0.0540
Live Trading Signals (every 1 min)
Forecast
1: 14:23 - $0.0540
Forecast 2: 15:13 - $0.0540
Forecast 3: 15:53 - $0.0540
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0586 (14.68% ) |
| Volume | 0.0050 mill |
| Avg. Vol. | 0.0458 mill |
| % of Avg. Vol | 10.94 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BLPH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BLPH
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Latest Press Releases
2022-01-10 07:00:00 - Press Release
Bellerophon To Present At The H.c. Wainwright Bioconnect 2022 Conference
Warren, n.j., jan. 10, 2022 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that naseem amin, m.d., chairman of bellerophon's board of directors, will present a corporate overview at the h.c. wainwright bioconnect 2022 conference, being held virtually january 10-13, 2022.
2021-09-07 08:30:00 - Press Release
Bellerophon To Present At The H.c. Wainwright 23rd Annual Global Investment Conference
Warren, n.j., sept. 07, 2021 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that fabian tenenbaum, chief executive officer, will present a corporate overview at the h.c. wainwright 23rd annual global investment conference, being held september 13-15, 2021.
2021-05-27 08:30:00 - Press Release
Bellerophon To Present At The Jefferies Virtual Healthcare Conference
Warren, n.j., may 27, 2021 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that fabian tenenbaum, chief executive officer, will present a corporate overview at the jefferies virtual healthcare conference, being held june 1-4, 2021.
2021-05-26 08:30:00 - Press Release
Bellerophon Appoints Naseem Amin, M.d. As Chairman Of Its Board Of Directors
Dr. amin has served as an independent director since 2015 and succeeds jonathan peacock following mr. peacock's retirement from the company's board dr. amin has served as an independent director since 2015 and succeeds jonathan peacock following mr. peacock's retirement from the company's board
2021-05-11 08:30:00 - Press Release
Bellerophon Provides Clinical Program Update And Reports First Quarter 2021 Financial Results
Warren, n.j., may 11, 2021 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended march 31, 2021.
Latest News
2023-07-25 08:46:32 - InvestorPlace
Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?
Bellerophon Therapeutics (NASDAQ: BLPH ) stock is losing value on Tuesday after the clinical-stage therapeutics company was sent a delisting notice. The Listing Qualifications Department for the Nasdaq Exchange has decided to delist shares of BLPH stock come Friday unless it requests a meeting with the Nasdaq Hearings Panel.
2023-07-05 08:51:09 - Benzinga
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-06-06 13:15:06 - Zacks Investment Research
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails
Bellerophon's (BLPH) shares fall as a late-stage study of INOpulse to treat fibrotic interstitial lung disease fails to meet its primary endpoint.
2023-06-06 10:44:14 - Zacks Investment Research
Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?
Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
2023-06-05 09:39:00 - Market Watch
Bellerphon Therapeutics stock plunges toward record selloff after lung disease treatment performs worse than placebo in late-stage trial
Shares of Bellerophon Therapeutics Inc. BLPH, -83.00% plummeted 83% toward a record one-day decline, after the biotherapeutics company said its lung-disease treatment failed to meet its primary endpoint in a Phase 3 “Rebuild” study. The company said its INOpulse for the treatment of fibrotic Interstitial Lung Disease (fILD) performed worse than placebo, while the secondary endpoints demonstrated “minimal difference” between studied groups, with none approaching statistical significance.
2023-06-05 09:12:40 - InvestorPlace
Why Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today?
Bellerophon Therapeutics (NASDAQ: BLPH ) stock is taking a massive beating on Monday after the pharmaceutical company posted poor clinical trial results. The bad news for BLPH stock comes from its Phase 3 clinical trial of INOpulse as a treatment for fibrotic Interstitial Lung Disease (fILD).
2023-04-03 08:22:16 - Zacks Investment Research
5 Stocks With Recent Price Strength Amid March Rally
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are BLPH, CRD.B, REPX, HROW and LNTH.
2023-03-28 09:56:17 - Zacks Investment Research
Bellerophon Therapeutics (BLPH) Is a Great Choice for 'Trend' Investors, Here's Why
Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
2023-03-10 09:57:15 - Zacks Investment Research
Here's Why Momentum in Bellerophon Therapeutics (BLPH) Should Keep going
Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
2023-01-06 06:00:00 - PennyStocks
How to Find Cheap Penny Stocks to Make Money Trading
Use these tips for finding cheap penny stocks to buy The post How to Find Cheap Penny Stocks to Make Money Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.